FDA Advisors Unanimously Back Moderna's mRNA Flu Vaccine

Independent advisors for the Food and Drug Administration on Friday voted 9–0 in support of approving Moderna's seasonal mRNA flu vaccine, which a Trump appointee at the agency initially tried to block from even being reviewed. The FDA's advisory committee, known as VRBPAC for Vaccines and Related Biological Products Advisory Committee, spent all day reviewing data and presentations on the vaccine, dubbed mRNA-1010 and branded as mFlusiva. The presentations included a review from FDA scientists, which was supportive of the vaccine.

Data from a Phase 3 trial including over 40,000 adults age 50 and older found the mRNA vaccine was around 27 percent more effective against seasonal flu than a standard flu shot. A smaller Phase 3 trial, involving data from nearly 3,000 people age 65 years and older, showed the shot produces stronger immune responses than a high-dose flu vaccine, which is recommended for this age group. The safety profile of the vaccine was also generally good.

The unanimous vote paves the way for the FDA to make a final decision on approving mFlusiva. If approved, the vaccine could offer a more effective option for preventing seasonal flu. Why this matters: The FDA's advisory committee vote in favor of Moderna's mRNA flu vaccine has significant implications for the future of flu prevention.

If approved, mFlusiva could provide a more effective alternative to traditional flu shots, potentially reducing the burden of seasonal flu on public health. For developers, this vote validates the potential of mRNA technology in vaccine development. For businesses and consumers, it offers hope for a more effective flu vaccine option.

However, questions remain about the long-term safety and efficacy of mRNA vaccines, as well as their potential applications beyond flu prevention. The FDA's final decision on approval will be closely watched, and could have a lasting impact on the vaccine development industry.